Epitan plans AIM listing
Thursday, 31 March, 2005
Melbourne's Epitan is planning to raise up to 15 million pounds (AUD$37 million) in a flotation on London's AIM stock market. EpiTan focuses on dermatology and its main product, Melanotan, helps treat sunburn injury.
The company said its London flotation would raise money to fund further development of Melanotan and increase its international profile. EpiTan is already listed on the Australian stock exchange.
"I am delighted to be able to introduce EpiTan to UK investors, particularly as we expect Europe to be a key market for our lead development product, Melanotan," said chief executive Iain Kirkwood.
Trading in the shares on AIM is due to begin in May. Investment bank Teather & Greenwood is the broker and adviser on the flotation.
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...